Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome

计划入组 80 人 · 首次发布于 2026 年 1 月 9 日

Proof-of-concept Study to Assess the Efficacy and Safety of SRX246 in Adults With PTSD

计划入组 33 人 · 首次发布于 2016 年 4 月 11 日

Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease

计划入组 106 人 · 首次发布于 2015 年 7 月 23 日

Mixed vasopressin receptor 1A agonist-antagonist(OCELOT)

Vasopressin(Vasostrict)

C₉₂H₁₃₀N₂₈O₂₄S₄ · Rx

Vasopressin Tannate

Arvinas Estrogen Receptor, Inc.

United States

Arvinas Androgen Receptor, Inc.

United States

Veru Inc

United States

Neumora's NMRA-511 Shows Clinically Meaningful Results in Phase 1b Alzheimer's Agitation Study

Neumora Therapeutics Awaits Key Data Readouts for Navacaprant in Major Depressive Disorder

Neumora Therapeutics Outlines 2026 Pipeline Strategy with Multiple Clinical Readouts Expected